RE:YOUTH (YONSEI BH Arterial Stemcell Clinic)
RE:YOUTH (YONSEI BH Arterial Stemcell Clinic)
Republic of Korea, Cheonan
Byung-hee Lee
42 years of experience
Clinic is certified :
Stem cell therapy for neuropathy in the Republic of Korea costs from $6,500 to $12,500. Prices vary based on the delivery method, cell source, and clinic specialization. In the US, similar procedures cost $25,000 on average. Patients save approximately 62% by choosing Korean medical centers. Standard packages typically include consultations, laboratory testing, cell processing, and the procedure.
Bookimed Expert Insight: Choosing arterial delivery offers specific value for neuropathy patients. RE:YOUTH (YONSEI BH) specializes in this method to target organs directly. This technique delivers cells more efficiently than standard IV drips. While specialized neurological protocols can reach $33,000, they often include KOIHA accredited care. Patients should budget for a 3-week stay to ensure proper monitoring after treatment.
| Republic of Korea | Turkey | Austria | |
| Stem cell therapy for neuropathy | ≈ $6,500 | from $7,000 | ≈ $5,500 |
No hidden fees – just official clinic prices. Pay at the clinic for Stem cell therapy for neuropathy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Stem cell therapy for neuropathy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Stem cell therapy for neuropathy journey.
Dr. Byung-hee Lee is a neurosurgeon at RE:YOUTH Clinic in South Korea. He is a founding member of the Korean Society of Interventional Neurology. He also helped found the Korean Stroke Society. Dr. Lee treats complex conditions like Parkinson's, Alzheimer's, and cerebral aneurysms.
Stem cell therapy is not a standard approved cure for neuropathy in South Korea. The Ministry of Food and Drug Safety strictly regulates these therapies. While Korean regenerative law allows limited access, neuropathy treatments remain investigational and typically occur within specialized research protocols or clinical trials.
Bookimed Expert Insight: While South Korea ranks 6th globally for medical requests, stem cell clinics here focus on exclusivity. For example, RE:YOUTH Clinic limits intake to 2 patients daily. This small-scale approach suggests these are specialized regenerative evaluations rather than mass-market medical solutions.
Patient Consensus: Evidence for nerve repair remains early and outcomes often vary between patients. You should verify the specific cell type and regulatory status with a neurologist before starting any treatment.
Stem cell therapy in South Korea aims to repair nerve damage by addressing root causes rather than masking symptoms. Specialists use mesenchymal stem cells to reduce neuroinflammation, stimulate new blood vessel growth, and release neurotrophic factors that support the survival and regrowth of damaged nerve fibers.
Bookimed Expert Insight: While most clinics use intravenous drips, RE:YOUTH in Cheonan offers specialized arterial stem cell therapy. This method targets the blood supply directly. The clinic limits intake to 2 patients daily. This focus on low volume suggests a shift toward highly personalized regenerative protocols.
Patient Consensus: Patients focus on recovering long-term sensation and circulation rather than seeking immediate pain relief. Some note that improvements in temperature perception and function can take 8 months to appear.
Patients qualify for stem cell therapy for neuropathy in South Korea if they have a confirmed neurological diagnosis via nerve conduction studies or electromyography. Candidates typically include those with refractory diabetic or peripheral neuropathy who have not responded to standard medical management or physical therapy.
Bookimed Expert Insight: South Korea is home to the only facility, RE:YOUTH clinic in Cheonan, that uses arterial stem cell therapy for chronic conditions. This clinic limits intake to only 2 patients daily to maintain high care standards. While 96 clinics exist in the region, this specific approach serves about 1,000 patients annually, showing a specialized focus on delivery methods over standard IV injections.
Patient Consensus: Neuropathy diagnosis alone does not guarantee treatment approval. Patients report that outcomes vary and strongly advise getting an independent neurologist's assessment to verify if nerve regeneration is realistic for their specific case.
International patients seeking stem cell therapy for neuropathy in South Korea must provide recent Electromyography (EMG) and Nerve Conduction Velocity (NCV) reports. Certified English translations of specialist-generated diagnostic notes, full laboratory blood panels, and digital DICOM imaging files are also required for clinical evaluation.
Bookimed Expert Insight: While most clinics use intravenous cells, RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) offers direct arterial infusion. This specialized approach aims to deliver cells closer to damaged nerve tissues. Patients should confirm which cell source, like adipose or bone-marrow-derived, the clinic plans to use before traveling.
Patient Consensus: Patients recommend bringing original lab files with reference ranges instead of just summary letters. A one-page English timeline of symptom progression helps doctors quickly understand your specific treatment goals.